CN110755523B - Composition for improving hyperglycemia and preparation method thereof - Google Patents
Composition for improving hyperglycemia and preparation method thereof Download PDFInfo
- Publication number
- CN110755523B CN110755523B CN201911081539.3A CN201911081539A CN110755523B CN 110755523 B CN110755523 B CN 110755523B CN 201911081539 A CN201911081539 A CN 201911081539A CN 110755523 B CN110755523 B CN 110755523B
- Authority
- CN
- China
- Prior art keywords
- composition
- filtering
- parts
- liquid medicine
- heating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 201000001421 hyperglycemia Diseases 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 47
- 239000007788 liquid Substances 0.000 claims abstract description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 238000001914 filtration Methods 0.000 claims abstract description 28
- 238000010438 heat treatment Methods 0.000 claims abstract description 22
- 239000000706 filtrate Substances 0.000 claims abstract description 17
- 238000009835 boiling Methods 0.000 claims abstract description 15
- 210000000582 semen Anatomy 0.000 claims abstract description 10
- 235000020234 walnut Nutrition 0.000 claims abstract description 10
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 9
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 9
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 9
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 9
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 9
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 8
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 8
- 238000002791 soaking Methods 0.000 claims abstract description 7
- 238000000605 extraction Methods 0.000 claims abstract description 6
- 238000001704 evaporation Methods 0.000 claims abstract description 5
- 240000007049 Juglans regia Species 0.000 claims abstract 3
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 6
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 2
- 240000002948 Ophiopogon intermedius Species 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 35
- 208000024891 symptom Diseases 0.000 abstract description 10
- 230000001684 chronic effect Effects 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 5
- 230000004060 metabolic process Effects 0.000 abstract description 5
- 239000000047 product Substances 0.000 abstract description 5
- 208000004880 Polyuria Diseases 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 208000030159 metabolic disease Diseases 0.000 abstract description 4
- 206010020710 Hyperphagia Diseases 0.000 abstract description 3
- 230000035619 diuresis Effects 0.000 abstract description 3
- 206010036067 polydipsia Diseases 0.000 abstract description 3
- 208000016261 weight loss Diseases 0.000 abstract description 2
- 230000004580 weight loss Effects 0.000 abstract description 2
- 239000008280 blood Substances 0.000 description 36
- 210000004369 blood Anatomy 0.000 description 36
- 241000699670 Mus sp. Species 0.000 description 32
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 239000008103 glucose Substances 0.000 description 18
- 230000037396 body weight Effects 0.000 description 13
- 230000037406 food intake Effects 0.000 description 8
- 235000012631 food intake Nutrition 0.000 description 8
- 241000758789 Juglans Species 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 238000003304 gavage Methods 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 244000248557 Ophiopogon japonicus Species 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000021050 feed intake Nutrition 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000000291 postprandial effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000081 effect on glucose Effects 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 208000022530 polyphagia Diseases 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition for improving hyperglycemia and a preparation method thereof, wherein the composition for improving hyperglycemia comprises the following effective components in parts by weight: 1-20 parts of Chinese yam; 1-20 parts of kudzu roots; 2-25 parts of walnut; the preparation method comprises the following steps: a liquid medicine extraction step: soaking rhizoma Dioscoreae, radix Puerariae, semen Cassiae, radix Ophiopogonis and semen Juglandis in water, boiling, and filtering to obtain medicinal liquid; and (3) filtering: heating and concentrating the medicinal liquid, adding ethanol, refrigerating, and filtering to obtain filtrate; a concentration step: heating the filtrate, and evaporating ethanol under reduced pressure to obtain composition; the composition can be used as both medicine and food, and can be used for improving metabolic disorder symptoms of diabetic patients after being taken by users, such as: the health care product has the advantages of preventing and treating symptoms of excessive eating, excessive drinking, diuresis and weight loss, maintaining good absorption and metabolism, improving the physique of a user and reducing the occurrence of chronic complications of diabetes.
Description
Technical Field
The invention relates to a composition for improving hyperglycemia and a preparation method thereof, belonging to the technical field of application of medicinal and edible plants.
Background
Diabetes is a metabolic disease characterized by hyperglycemia. Hyperglycemia is caused by a defect in insulin secretion or an impaired biological action, or both. Hyperglycemia occurring in the long term of diabetes results in chronic damage to, and dysfunction of, various tissues, particularly the eyes, kidneys, heart, blood vessels, nerves. Diabetes is another persistent disease following cardiovascular diseases, the incidence rate is increasing, complete cure cannot be achieved, and many complications exist, the current treatment scheme mainly adopts long-term application of insulin and hypoglycemic drugs, and the chemical hypoglycemic drugs have side effects of different degrees and are not beneficial to long-term administration, so how to balance blood sugar control and side effect reduction is a great direction for drug research. The traditional Chinese medicine culture is profound, and the traditional Chinese medicine preparation has small toxic and side effects and high safety, and gradually becomes a hotspot of research.
Disclosure of Invention
In order to overcome the defects of the prior art, the first object of the invention is to provide a composition for improving hyperglycemia, which can be used as both medicine and food, and after being eaten by a user, the composition can reduce the food intake and water intake, improve the metabolic disturbance comprehensive symptoms of a diabetic patient, maintain good absorption and metabolism, improve the physique of the user, and reduce the occurrence of chronic complications of diabetes.
The second object of the present invention is to provide a method for preparing the composition for improving hyperglycemia, which can extract the essence of the composition components so that the composition can exert optimal efficacy.
The first purpose of the invention can be achieved by adopting the following technical scheme: a composition for improving hyperglycemia comprises the following effective components in parts by weight:
1-20 parts of Chinese yam;
1-20 parts of kudzu roots;
2-25 parts of walnut.
Further, the composition also comprises 2-15 parts of cassia seed.
Further, the composition also comprises 2-15 parts of dwarf lilyturf tuber.
Further, the composition comprises the following effective components in parts by weight:
further, the composition comprises the following effective components in parts by weight:
further, the composition comprises the following effective components in parts by weight:
the second purpose of the invention can be achieved by adopting the following technical scheme: a method for preparing a composition for improving hyperglycemia as described above, comprising:
a liquid medicine extraction step: soaking rhizoma Dioscoreae, radix Puerariae, semen Cassiae, radix Ophiopogonis and semen Juglandis in water, boiling, and filtering to obtain medicinal liquid;
and (3) filtering: heating and concentrating the medicinal liquid, adding ethanol, refrigerating, and filtering to obtain filtrate;
a concentration step: heating the filtrate, and evaporating ethanol under reduced pressure to obtain the composition.
Further, in the liquid medicine extraction step, adding water 4-6 times of the total weight of the Chinese yam, the kudzuvine root, the cassia seed, the dwarf lilyturf tuber and the walnut for soaking, heating and boiling for 60min, and filtering out primary liquid medicine; then adding 3-4 times of water, heating and boiling for 45min, and filtering out the secondary liquid medicine; adding 2-3 times of water, heating and boiling for 30min, and filtering to obtain three times of medicinal liquid; mixing the primary liquid medicine, the secondary liquid medicine and the tertiary liquid medicine.
Further, in the filtering step, the liquid medicine is heated and concentrated to the concentration of 0.7-1 g/mL; then adding 95 vt% ethanol with the same volume as the concentrated liquid medicine, stirring well, refrigerating, and centrifuging or filtering with Buchner funnel.
Further, in the concentration step, the filtrate is heated and ethanol is distilled out under reduced pressure until the volume is 50% of the volume of the filtrate, so that the composition is obtained.
The formulation design principle of the invention is as follows:
diabetes belongs to the category of diabetes in traditional Chinese medicine, and the pathogenesis of diabetes is spleen qi weakness, phlegm and blood stasis, deficiency, phlegm, turbidity and toxicity coexisting in traditional Chinese medicine. In the formula, the Chinese yam is also called Chinese yam, and can tonify spleen and stomach, tonify lung and kidney, and treat deficiency of vital energy and dyspepsia; radix Puerariae is dried root of Pueraria lobata Ohwi of Leguminosae, and has effects of promoting fluid production to quench thirst, clearing away heat and promoting eruption, lowering blood sugar, improving memory, invigorating yang and relieving diarrhea; it is commonly used for exterior syndrome with fever, strong pain of neck and back, measles without adequate eruption, thirst due to fever, diabetes due to yin deficiency, dysentery due to heat-purging and diarrhea due to spleen deficiency; the walnut has the effects of warming lung, tonifying kidney, benefiting liver, strengthening brain, strengthening tendons and bones and the like; the walnut contains rich unsaturated fatty acid, can effectively relieve the resistance of the body to insulin, and can effectively reduce blood sugar. Contains a large amount of walnut oil, can moisten intestines, treat constipation and increase weight of people with emaciation.
When the safe and nontoxic plants with homology of medicine and food are used in combination, the effects of the plant composition can improve the symptoms of polydipsia, polyphagia, diuresis and weight loss of diabetics, and the reduction of the food consumption is favorable for reducing the blood sugar, but simultaneously improves the metabolism of human bodies, strengthens the physique, resists the reduction of the weight, improves various functions of the bodies and reduces the generation of chronic complications.
Compared with the prior art, the invention has the beneficial effects that:
1. the composition for improving the hyperglycemia belongs to the medicine and food dual purpose, and after being eaten by a user, the composition reduces the food intake and the water intake, improves the polyuria symptom, improves the metabolic disorder symptom of a diabetic patient, maintains good absorption and metabolism, improves the physique of the user, and reduces the occurrence of chronic complications of the diabetes;
2. the composition for improving hyperglycemia has the effects of reducing blood sugar, resisting oxidation, regulating blood pressure, protecting islet cells, promoting the repair of damaged cells, protecting optic nerves, correcting metabolic disorder of a diabetic patient and reducing the occurrence of chronic complications of diabetes;
3. the composition for improving hyperglycemia can generate the effects of tonifying spleen and qi, eliminating phlegm and removing blood stasis, tonifying kidney and arresting seminal emission, promoting the secretion of saliva or body fluid and quenching thirst, clearing liver and improving eyesight, and detoxifying and tonifying deficiency for a user, and is a research result which is carried out by taking the pathogenesis of diabetes as a starting point in traditional Chinese medicine;
4. the preparation method of the composition for improving hyperglycemia can extract essence of composition components, so that the composition can exert optimal efficacy.
Detailed Description
The invention will be further described with reference to specific embodiments:
a composition for improving hyperglycemia comprises the following effective components in parts by weight:
cassia seed, bitter, sweet, salty and slightly cold in nature, enters liver, kidney and large intestine meridians; the composition has the effects of relaxing bowel, reducing blood fat and improving eyesight, is beneficial to generating a synergistic effect with walnuts when being added into the composition, and improves the kidney qi and strengthens the foundation; the dwarf lilyturf tuber is sweet and slightly bitter in taste and slightly cold in nature, enters stomach, lung and heart channels, has the effects of nourishing yin, moistening lung, benefiting stomach, promoting fluid production, clearing heart fire and relieving restlessness, has the effects of promoting gastrointestinal functions and absorption of a human body by cooperating with the Chinese yam and the kudzuvine root, improves metabolism of the human body, improves immunity and reduces the generation of complications caused by high blood sugar.
The preparation method of the composition comprises the following steps:
a liquid medicine extraction step: adding water 4-6 times of the total weight of rhizoma Dioscoreae, radix Puerariae, semen Cassiae, radix Ophiopogonis and semen Juglandis, soaking, heating and boiling for 60min, and filtering to obtain primary medicinal liquid; then adding 3-4 times of water, heating and boiling for 45min, and filtering out the secondary liquid medicine; adding 2-3 times of water, heating and boiling for 30min, and filtering to obtain three times of medicinal liquid; combining the primary liquid medicine, the secondary liquid medicine and the tertiary liquid medicine to form liquid medicine;
and (3) filtering: heating and concentrating the liquid medicine to the concentration of 0.7-1 g/mL; adding 95 vt% ethanol with the same volume as the concentrated medicinal liquid, stirring, refrigerating, centrifuging or filtering with Buchner funnel, and collecting filtrate;
a concentration step: heating the filtrate, and evaporating ethanol under reduced pressure to obtain a volume of 50% of the filtrate to obtain the composition.
Examples 1-2 include the active ingredients shown in table 1 in parts by weight:
TABLE 1 weight ratio of examples 1-2
| Composition (I) | Example 1 | Example 2 |
| Chinese yam | 10 portions of | 6 portions of |
| Kudzu root | 10 portions of | 6 portions of |
| Cassia seed | 6 portions of | 7 portions of |
| Ophiopogon japonicus | 6 portions of | 7 portions of |
| Walnut (walnut) | 8 portions of | 10 portions of |
The preparation of examples 1 and 2 is as follows:
a liquid medicine extraction step: adding water 5 times of the total weight of rhizoma Dioscoreae, radix Puerariae, semen Cassiae, radix Ophiopogonis and semen Juglandis, soaking, heating and boiling for 60min, and filtering to obtain primary medicinal liquid; then adding 4 times of water, heating and boiling for 45min, and filtering out the secondary liquid medicine; adding 3 times of water, heating and boiling for 30min, and filtering to obtain three times of medicinal liquid; combining the primary liquid medicine, the secondary liquid medicine and the tertiary liquid medicine to form liquid medicine;
and (3) filtering: heating and concentrating the liquid medicine to a concentration of 1g/mL, adding 95 vt% ethanol with the same volume as the concentrated liquid medicine, stirring uniformly, refrigerating, centrifuging or filtering with a Buchner funnel, and taking the filtrate;
a concentration step: heating the filtrate, and evaporating ethanol under reduced pressure to obtain a volume of 50% of the filtrate to obtain the composition.
And (3) detection:
animal experiment research on the pharmacodynamics of the formula for treating diabetes mellitus is carried out:
1. experimental materials:
1.1 animals: kunming mice were provided by southern university of medical laboratory animal center.
1.2 reagent: streptozotocin (STZ) is a product of Sigma company, and other reagents are domestic analytical pure products.
1.3 glucometer: the steady blood glucose meter (OneTouch Ultra) and the test paper are products of the american powerhouse company.
1.4 composition of example 1: prepared as described in example 1.
1.5 metformin hydrochloride tablets (0.25 g/tablet): shenzhen, a product of Zhonglian pharmaceutical Co.
2. The experimental method comprises the following steps:
2.1 establishment of a streptozotocin delayed-onset diabetes model: streptozotocin was dissolved in 0.1mol/L sodium citrate buffer (pH 4.2) just before use to prepare a solution of 4 mg/mL. Male Kunming mice, weighing 18-22g, were fasted overnight daily and then intraperitoneally injected with streptozotocin solution at 0.1mL/10g body weight, i.e., 40mg/kg, for 5 consecutive days, for a total of 200 mg/kg. 2 weeks after the start of molding, the mice were caudally clipped to take blood and blood glucose was measured with a glucometer. Selecting mice with blood sugar level between 200mg/dL-450mg/dL as mice successfully modeled after diabetes mellitus to enter the experiment.
2.2 Experimental groups and methods of administration: diabetic mice were randomly divided into 4 groups. The test drugs were administered by gavage to a model control group (distilled water 0.2mL/10g body weight), a positive control group (metformin 200mg/kg body weight administration), a high dose group (0.3 mL/10g body weight administration to mice) of example 1, and a low dose group (0.2 mL/10g body weight administration to mice) of example 1, respectively.
2.3 detection of diabetes index:
2.3.1 blood glucose determination: after the diabetic mice are continuously dosed for 7 days and 21 days, fasting and water prohibition are performed at night, and fasting blood glucose is measured after fasting for 14 hours. Then, the administration was carried out, and then, free ingestion and drinking were resumed, and blood glucose 6 hours after resumption of normal diet was determined as postprandial blood glucose.
2.3.2 glucose tolerance assay: starch is added into each group of the medicine liquid according to the intragastric administration amount of 3g/kg, and is mixed evenly before use. The diabetic mice are continuously administrated for 21 days, fasting is carried out at night without water supply, the tail venous blood of the mice is taken after 14 hours to measure the fasting blood sugar as the blood sugar of 0min, the medicines added with starch are immediately intragastrically filled, and the blood sugar levels at 30min, 60min and 120min after intragastrically filled are respectively measured.
2.3.3 feed intake coefficient and water intake coefficient: when the diabetic mice were gazed for 21 days, the food intake and water intake for 24 hours in each group were measured, the body weight was measured, and the food intake coefficient (feed amount/body weight) and the water intake coefficient (water intake/body weight) were calculated, respectively.
2.4 statistical analysis: significance was compared between each dosing group and the model control group (X ± SD) using the inter-group t-test.
3. As a result:
3.1 effects of blood glucose levels in diabetic mice:
the experimental results are shown in table 2, and the high dose and the low dose of example 1 were administered for 7 days continuously, and although the fasting blood glucose level of diabetic mice did not significantly decrease (there was no significant difference in the metformin-positive drug group), the postprandial blood glucose increase was significantly suppressed. The postprandial blood glucose levels of the high and low dose groups were reduced by 19.7% (P <0.01) and 12.1% (P <0.05), respectively, compared to the model control. When high and low doses were given continuously for 21 days (see table 30min blood glucose), the fasting blood glucose was significantly different from that of the model control (P < 0.05).
Table 2 blood glucose measurement results (mmoL/L) (n ═ 11)
*: p <0.05 compared to model control; **: p <0.01 compared to model control.
Simulating the regular diet of human, adopting the method of taking after fasting and gavage administration before meal to observe the influence of the composition on the blood sugar after meal. The results show that the high dose and the low dose can remarkably inhibit the rise of the blood sugar after meal, and the maintenance time is long, and the high dose and the low dose still have significance after 6h of meal. After the stomach is perfused for 7 days, the blood sugar of the model control group is 446.5mg/mL after 6 hours of meal, the high dose is 358.6mg/mL (P <0.01), and the inhibition rate is 19.7%.
3.2 effects of glucose tolerance in diabetic mice:
as seen from the blood glucose results in Table 3, the fasting blood glucose (P <0.05) was significantly reduced in mice at 21 days of gavage with both high and low doses, but did not reduce the rise in blood glucose levels after gavage with starch. I.e. no effect on glucose tolerance.
Table 3 results of sugar tolerance measurement (mmoL/L) (n ═ 11)
*: p <0.05 compared to model control; **: p <0.01 compared to model control.
3.3 improvement of diabetic mouse symptoms:
gavage administration significantly improved the symptoms in diabetic mice, with the results shown in table 4. The weight of the mice averagely increases 2.8g after the high dose gastric lavage for 21 days, while the weight of the mice in the model control group averagely increases 1.8g, which has significant difference (P < 0.05). The low-dose gastric lavage can also reduce the food intake coefficient and the water intake coefficient of diabetic mice, the food intake coefficient of the mice is respectively reduced by 16.5 percent and 10.2 percent by the high dose and the low dose, and the water intake coefficient of the mice is respectively reduced by 36.5 percent and 23.5 percent. The high dose and the low dose obviously improve the symptoms of polydipsia, diuresis and polyphagia of the diabetic mice, the activity of the mice is more agile and powerful, and the appearance conditions such as hair color and the like are better than those of the control group of mice. The mice were healthy and viable compared to the model group in terms of signs.
TABLE 4 influence on body weight, feed intake coefficient and water intake coefficient of diabetic mice
*: p <0.05 compared to model control.
3.4 effects on body weight and food and water intake in normal mice:
the normal mice were gavaged for 9 consecutive days at high doses and the effects of the high doses on the normal mice body weight, feed intake coefficient and water intake coefficient were observed, and the results are shown in table 5. As seen from the results in table 5, the high dose had no significant effect on normal mouse body weight, food intake and water intake.
Table 5 influence on body weight, feed intake coefficient and water intake coefficient of normal mice (n ═ 13)
Experimental results show that the high-dose and low-dose hyperglycemia improving composition in example 1 can remarkably reduce postprandial blood sugar of diabetic mice, has a certain effect of reducing fasting blood sugar, and improves symptoms of diabetes and constitution of the diabetic mice. But had no effect on glucose tolerance in mice.
Various other changes and modifications to the above-described embodiments and concepts will become apparent to those skilled in the art from the above description, and all such changes and modifications are intended to be included within the scope of the present invention as defined in the appended claims.
Claims (1)
1. The preparation method of the composition for improving hyperglycemia is characterized in that the composition comprises the following effective components in parts by weight: 10 parts of Chinese yam, 10 parts of kudzu root, 6 parts of cassia seed, 6 parts of dwarf lilyturf tuber and 8 parts of walnut;
the preparation method comprises the following steps of: soaking rhizoma Dioscoreae, radix Puerariae, semen Cassiae, radix Ophiopogonis and semen Juglandis in water, boiling, and filtering to obtain medicinal liquid; and (3) filtering: heating and concentrating the medicinal liquid, adding ethanol, refrigerating, and filtering to obtain filtrate; a concentration step: heating the filtrate, and evaporating ethanol under reduced pressure to obtain composition;
wherein, in the liquid medicine extraction step, water which is 4-6 times of the total weight of the Chinese yam, the kudzuvine root, the cassia seed, the dwarf lilyturf tuber and the walnut is added for soaking, the heating and the boiling are carried out for 60min, and the liquid medicine is filtered out once; then adding 3-4 times of water, heating and boiling for 45min, and filtering out the secondary liquid medicine; adding 2-3 times of water, heating and boiling for 30min, and filtering to obtain three times of medicinal liquid; mixing the primary liquid medicine, the secondary liquid medicine and the tertiary liquid medicine;
in the filtering step, the liquid medicine is heated and concentrated to the concentration of 0.7-1 g/mL; then adding 95 vt% ethanol with the same volume as the concentrated liquid medicine, stirring uniformly, refrigerating, and centrifuging or filtering with Buchner funnel;
in the concentration step, the filtrate is heated and ethanol is evaporated under reduced pressure until the volume of the filtrate is 50% of the volume of the filtrate, so that the composition is obtained.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911081539.3A CN110755523B (en) | 2019-11-07 | 2019-11-07 | Composition for improving hyperglycemia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911081539.3A CN110755523B (en) | 2019-11-07 | 2019-11-07 | Composition for improving hyperglycemia and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110755523A CN110755523A (en) | 2020-02-07 |
| CN110755523B true CN110755523B (en) | 2022-02-15 |
Family
ID=69336722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911081539.3A Active CN110755523B (en) | 2019-11-07 | 2019-11-07 | Composition for improving hyperglycemia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110755523B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106729432A (en) * | 2017-01-19 | 2017-05-31 | 贾庭山 | A kind of Chinese medicine composition for treating cardiovascular and cerebrovascular disease |
-
2019
- 2019-11-07 CN CN201911081539.3A patent/CN110755523B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106729432A (en) * | 2017-01-19 | 2017-05-31 | 贾庭山 | A kind of Chinese medicine composition for treating cardiovascular and cerebrovascular disease |
Non-Patent Citations (4)
| Title |
|---|
| 余传林等.血糖安抗糖尿病作用的实验研究.《第十届全国抗炎免疫药理学学术会议论文集》.2011,第117-119页，尤其是第117页倒数第6-7行以及第118页第2行. * |
| 葛根降糖胶囊水提醇沉工艺的研究;陈建真等;《世界科学技术-中医药现代化》;20061230;第8卷(第6期);第46-49页，尤其是第46页左栏第1段 * |
| 血糖安抗糖尿病作用的实验研究;余传林等;《第十届全国抗炎免疫药理学学术会议论文集》;20110620;第117-119页，尤其是第117页倒数第6-7行以及第118页第2行 * |
| 陈建真等.葛根降糖胶囊水提醇沉工艺的研究.《世界科学技术-中医药现代化》.2006,第8卷(第6期),第46-49页，尤其是第46页左栏第1段. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110755523A (en) | 2020-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102048933B (en) | Chinese medicinal composition for treating infantile diarrhea and preparation method thereof | |
| CN102198262B (en) | Chinese medicine preparation for treating infant rotavirus enteritis and preparation method thereof | |
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN105815647A (en) | Solid drink capable of dispelling effect of alcohol and protecting liver and preparation method and application thereof | |
| CN1613383A (en) | Green healthy beverage | |
| CN102784230B (en) | Pharmaceutical composition preparation for treating nutritional anemia | |
| CN110755523B (en) | Composition for improving hyperglycemia and preparation method thereof | |
| CN102091228B (en) | Medicine for treating insomnia and preparation method thereof | |
| CN102133283B (en) | Medicine for treating constipation and preparation method thereof | |
| CN103750304B (en) | Weight-reducing, fat-reducing and health-protection rhizoma alismatis oral liquid and preparation method thereof | |
| CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
| CN106234699A (en) | The medicated tea of a kind of heat clearing away Xuanhua treatment heating and preparation processing method | |
| CN110916036A (en) | Liquor and preparation method thereof | |
| NL2037306B1 (en) | A nutritional product for clearing and protecting the lungs and a preparation method thereof | |
| CN104524003A (en) | Traditional Chinese medicine composition with golden camellia and radix pueraiae | |
| CN112076305A (en) | A Chinese medicinal oral and topical stock solution mixture for treating metabolic syndrome and resisting bacteria and inflammation | |
| CN102198174A (en) | Traditional Chinese medicine formulated preparation for nourishing kidney, removing heat from liver, reducing sugar and regulating fat, and preparation method thereof | |
| CN107213283A (en) | A kind of antifatigue, Yin Yang balancing food and medicament dual-purpose Chinese medicine composition and preparation method thereof | |
| CN102309572A (en) | Blood nourishing oral liquid and preparation method thereof | |
| CN107625863B (en) | Compound traditional Chinese medicine soft capsule for treating rheumatism bone disease and preparation method thereof | |
| CN106728828A (en) | A kind of Chinese medicine preparation and its preparation technology for treating coronary heart disease | |
| CN106165798A (en) | A kind of heat-clearing and toxic substances removing health beverage and preparation processing method | |
| CN106173037A (en) | A kind of solid spleen kidney removing dampness prostatitic medicated tea of turbid treatment and preparation processing method | |
| CN106165807A (en) | A kind of replenishing YIN and removing heat the kidney invigorating beverage and preparation processing method | |
| CN105147944A (en) | Traditional Chinese medicine composition, preparation of traditional Chinese medicine composition and preparation method and application of preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230705 Address after: Building 2, No. 468 Guanghua Third Road, Baiyun District, Guangzhou City, Guangdong Province, 510510 Patentee after: Yun Kang Da health industry (Guangzhou) Co.,Ltd. Address before: 510510 Dongyuan community, Southern Medical University, Zhongcheng intersection, shatai Road, Baiyun District, Guangzhou, Guangdong Province Patentee before: Yu Chuanlin |
|
| TR01 | Transfer of patent right |